{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:09:39Z","timestamp":1778764179724,"version":"3.51.4"},"reference-count":140,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2TR000455"],"award-info":[{"award-number":["KL2TR000455"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL127251"],"award-info":[{"award-number":["K23HL127251"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3 DA048502"],"award-info":[{"award-number":["UG3 DA048502"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH120262"],"award-info":[{"award-number":["R01 MH120262"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PPG MIPS R01 HL088726"],"award-info":[{"award-number":["PPG MIPS R01 HL088726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL136205"],"award-info":[{"award-number":["R01 HL136205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL125246"],"award-info":[{"award-number":["R01HL125246"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PO1 HL101398"],"award-info":[{"award-number":["PO1 HL101398"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1TR002382"],"award-info":[{"award-number":["TL1TR002382"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL109413-02S1"],"award-info":[{"award-number":["R01HL109413-02S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 MH076955"],"award-info":[{"award-number":["K24 MH076955"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24HL077506"],"award-info":[{"award-number":["K24HL077506"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000454"],"award-info":[{"award-number":["UL1TR000454"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 HL149982"],"award-info":[{"award-number":["K01 HL149982"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007745-30"],"award-info":[{"award-number":["5T32HL007745-30"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R38AI140299"],"award-info":[{"award-number":["R38AI140299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL130025-06"],"award-info":[{"award-number":["T32 HL130025-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacl.2026.02.021","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:08:19Z","timestamp":1772309299000},"page":"869-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dyslipidemia and therapies after heart transplantation: Current\u00a0evidence and future directions"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-4445","authenticated-orcid":false,"given":"Adithya K.","family":"Yadalam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1214-9469","authenticated-orcid":false,"given":"Matthew E.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishan J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-0876","authenticated-orcid":false,"given":"Alexander C.","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambre","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Britt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy M.","family":"Book","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brett Rollins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"van Beuningen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-1962","authenticated-orcid":false,"given":"J. David","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshed A.","family":"Quyyumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-6370","authenticated-orcid":false,"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.02.021_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2014.08.003","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation","volume":"33","author":"Lund","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib2","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0735-1097(92)90340-S","article-title":"Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations","volume":"19","author":"Ballantyne","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.healun.2006.05.001","article-title":"Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients","volume":"25","author":"Kobashigawa","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib5","first-page":"319","article-title":"Cardiac allograft vasculopathy: a review","volume":"48","author":"Ramzy","year":"2005","journal-title":"Can J Surg"},{"key":"10.1016\/j.jacl.2026.02.021_bib6","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.ajt.2023.02.008","article-title":"OPTN\/SRTR 2021 Annual Data Report: heart","volume":"23","author":"Colvin","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib7","first-page":"133","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.02.021_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100079","article-title":"Prevalence, treatment, and control of severe hyperlipidemia","volume":"3","author":"Gold","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib9","first-page":"252","article-title":"Statins in familial hypercholesterolemia","volume":"68","author":"Besseling","year":"2016","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib10","first-page":"2625","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2026.02.021_bib11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/jcm12031233","article-title":"Opportunistic genetic screening for familial hypercholesterolemia in heart transplant patients","volume":"12","author":"Salgado","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","article-title":"Post-transplant dyslipidemia: mechanisms, diagnosis and management","volume":"6","author":"Agarwal","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib13","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/00007890-200204270-00012","article-title":"Risk factors for the development and progression of dyslipidemia after heart transplantation","volume":"73","author":"Akhlaghi","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib15","series-title":"Clinical Guide to Heart Transplantation","author":"Kobashigawa","year":"2017"},{"key":"10.1016\/j.jacl.2026.02.021_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation","volume":"42","author":"Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2026.02.021_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.36628\/ijhf.2020.0034","article-title":"Heart transplant immunosuppression strategies at Cedars-Sinai Medical Center","volume":"3","author":"Chang","year":"2021","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.jacl.2026.02.021_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0896-8411(92)90030-T","article-title":"Molecular mode of action of cyclosporin and FK506in human thymocytes","volume":"5","author":"Reem","year":"1992","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jacl.2026.02.021_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cis.2008.01.001","article-title":"The Conference on Membrane electrochemistry. Foreword","volume":"139","author":"Starov","year":"2008","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.jacl.2026.02.021_bib20","first-page":"1307","article-title":"Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen","volume":"8","author":"Helmschrott","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jacl.2026.02.021_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.healun.2008.10.004","article-title":"Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis","volume":"28","author":"Ye","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib22","first-page":"231","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.02.021_bib23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0002-9149(88)90272-X","article-title":"Frequency of hypercholesterolemia after cardiac transplantation","volume":"62","author":"Stamler","year":"1988","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib24","first-page":"807","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12291-012-0251-6","article-title":"Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients","volume":"28","author":"Ciftci","year":"2013","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.jacl.2026.02.021_bib26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/00007890-200004270-00012","article-title":"Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine","volume":"69","author":"Aleksic","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/00007890-200111270-00015","article-title":"Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS\/ISHLT Thoracic Registry","volume":"72","author":"Hosenpud","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib28","first-page":"444","article-title":"Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience","volume":"13","author":"Kirklin","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients1","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib30","first-page":"571","article-title":"Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation","volume":"13","author":"Taylor","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib31","first-page":"135","article-title":"Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids","volume":"39","author":"Akman","year":"2007","journal-title":"Transplant\u00a0Proc"},{"key":"10.1016\/j.jacl.2026.02.021_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","article-title":"Long-term sirolimus for primary immunosuppression in heart transplant recipients","volume":"71","author":"Asleh","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.02.021_bib34","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2026.02.021_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12265-016-9719-8","article-title":"Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients","volume":"10","author":"Simha","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.jacl.2026.02.021_bib36","first-page":"531","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib38","first-page":"626","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib39","first-page":"536","article-title":"Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients","volume":"21","author":"Tenderich","year":"2007","journal-title":"Clin\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib40","first-page":"1203","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib42","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1399-0012.2008.00868.x","article-title":"Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection","volume":"22","author":"Teuteberg","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib43","unstructured":"Cohen D.J. Action, efficacy and toxicities: corticosteroids. Primer on Transplantation. Mt Laurel, NJ: American Society of Transplantation; 2001:146-151."},{"key":"10.1016\/j.jacl.2026.02.021_bib44","first-page":"632","article-title":"Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients","volume":"85","author":"Becker","year":"1988","journal-title":"Am\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(93)90177-V","article-title":"Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus","volume":"104","author":"Bagdade","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.02.021_bib46","first-page":"68","article-title":"Metabolic risk factors for atherosclerosis in heart transplant recipients","volume":"128","author":"Kemna","year":"1994","journal-title":"Am\u00a0Heart J"},{"key":"10.1016\/j.jacl.2026.02.021_bib47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2165\/00003495-200464100-00003","article-title":"Management of hyperlipidaemia associated with heart transplantation","volume":"64","author":"Wenke","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2026.02.021_bib48","first-page":"1370","article-title":"HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms?","volume":"96","author":"Valantine","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib50","first-page":"621","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib51","first-page":"1736","article-title":"Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients","volume":"24","author":"Kobashigawa","year":"2005","journal-title":"J\u00a0Heart\u00a0Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib52","article-title":"Impact of statin use after heart transplantation","volume":"9","author":"Vallakati","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","article-title":"Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients","volume":"1","author":"Asberg","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib54","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.athoracsur.2020.02.005","article-title":"Preoperative statin therapy and heart transplantation outcomes","volume":"110","author":"Peled","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacl.2026.02.021_bib55","first-page":"e1","article-title":"The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J\u00a0Heart\u00a0Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib56","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ehf2.12784","article-title":"Statin intensity and risk for cardiovascular events after heart transplantation","volume":"7","author":"Golbus","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacl.2026.02.021_bib57","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.07","article-title":"Effect of statin intensity on the progression of cardiac allograft vasculopathy","volume":"7","author":"Ellimuttil","year":"2021","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.jacl.2026.02.021_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circulation Res"},{"key":"10.1016\/j.jacl.2026.02.021_bib60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2022.07.004","article-title":"Statin therapy for the primary prevention of cardiovascular disease: pros","volume":"356","author":"Razavi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.02.021_bib61","first-page":"42","article-title":"The role of statins in patients after heart transplantation","volume":"12","author":"Szygula-Jurkiewicz","year":"2015","journal-title":"Kardiochir Torakochirurgia Pol"},{"key":"10.1016\/j.jacl.2026.02.021_bib62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/TP.0b013e318183eefa","article-title":"Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells","volume":"86","author":"Yi","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib63","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.111.081059","article-title":"Statins and the risk of cancer after heart transplantation","volume":"126","author":"Fr\u00f6hlich","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-008-0541-2","article-title":"Potential immunologic effects of statins in cancer following transplantation","volume":"58","author":"Fildes","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jacl.2026.02.021_bib65","first-page":"1287","article-title":"Studies of cholesterol biosynthesis: V. The time course and pathway of the later stages of cholesterol biosynthesis in the livers of intact rats","volume":"238","author":"Goodman","year":"1963","journal-title":"J\u00a0Biol\u00a0Chem"},{"key":"10.1016\/j.jacl.2026.02.021_bib66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.jacl.2026.02.021_bib67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1183\/09031936.00134707","article-title":"Statins inhibit matrix metalloproteinase release from human lung fibroblasts","volume":"35","author":"Kamio","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacl.2026.02.021_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000470","article-title":"Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1","volume":"2","author":"Nabatov","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2026.02.021_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2005.10.015","article-title":"Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages","volume":"188","author":"Veillard","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.02.021_bib70","first-page":"189","article-title":"Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease","volume":"24","author":"Walter","year":"2010","journal-title":"In Vivo"},{"key":"10.1016\/j.jacl.2026.02.021_bib71","first-page":"539","article-title":"Isoprenoid regulation of cell growth: Identification of mevalonate-labelled compounds inducing DNA synthesis in human breast cancer cells depleted of serum and mevalonate","volume":"155","author":"Wejde","year":"1993","journal-title":"J\u00a0Cell\u00a0Physiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib72","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib73","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1053-2498(01)00369-2","article-title":"Safety and efficacy of atorvastatin in heart transplant recipients","volume":"21","author":"Patel","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib74","first-page":"565","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin\u00a0Pharmacol\u00a0Ther"},{"key":"10.1016\/j.jacl.2026.02.021_bib75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028019871891","article-title":"Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions","volume":"54","author":"Migliozzi","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2026.02.021_bib76","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","article-title":"CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus","volume":"4","author":"Lemahieu","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib77","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.healun.2011.08.004","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report\u20142011","volume":"30","author":"Christie","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13454","article-title":"Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus","volume":"33","author":"Heeney","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib79","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.healun.2009.03.014","article-title":"Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin","volume":"28","author":"Skalicka","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib80","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/TP.0b013e3181910eb2","article-title":"Safety and efficacy of statin therapy in patients switched from cyclosporine A to sirolimus after cardiac transplantation","volume":"86","author":"Aliabadi","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib81","first-page":"222","article-title":"Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus","volume":"42","author":"Kovarik","year":"2002","journal-title":"J\u00a0Clin\u00a0Pharmacol"},{"key":"10.1016\/j.jacl.2026.02.021_bib82","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib83","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1016\/j.transproceed.2011.08.052","article-title":"In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: a cross-sectional study","volume":"43","author":"Zakliczynski","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jacl.2026.02.021_bib84","first-page":"639","article-title":"Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy","volume":"22","author":"Konstandin","year":"2008","journal-title":"Clin\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib85","first-page":"249","article-title":"Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy","volume":"23","author":"Le","year":"2009","journal-title":"Clin\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib86","first-page":"2389","article-title":"Ezetimibe in heart transplantation: initial experience","volume":"39","author":"Moro","year":"2007","journal-title":"Transplant\u00a0Proc"},{"key":"10.1016\/j.jacl.2026.02.021_bib87","first-page":"1035","article-title":"Efficacy and tolerability of ezetimibe 10 mg\/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study\u2014the Ezetrol Add-On Study","volume":"22","author":"Bissonnette","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib88","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1177\/1060028013504077","article-title":"An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors","volume":"47","author":"Makkar","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2026.02.021_bib89","first-page":"281","article-title":"Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients","volume":"26","author":"Patel","year":"2007","journal-title":"J\u00a0Heart\u00a0Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib90","first-page":"321","article-title":"Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects","volume":"46","author":"Bergman","year":"2006","journal-title":"J\u00a0Clin\u00a0Pharmacol"},{"key":"10.1016\/j.jacl.2026.02.021_bib91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/0091270005284852","article-title":"Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients","volume":"46","author":"Bergman","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2026.02.021_bib92","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e318198d7d0","article-title":"The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin","volume":"87","author":"Shaw","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib93","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/clpt.2011.4","article-title":"Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers","volume":"89","author":"Oswald","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2026.02.021_bib94","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11897-023-00604-2","article-title":"PCSK9 inhibition in patients after heart transplantation: a retrospective review and literature analysis","volume":"20","author":"Chapa","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacl.2026.02.021_bib95","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/TP.0000000000002944","article-title":"PCSK9 inhibitor use in heart transplant recipients: a case series and review of the literature","volume":"104","author":"Jennings","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib96","series-title":"Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients","author":"Di Nora","year":"2019"},{"key":"10.1016\/j.jacl.2026.02.021_bib97","first-page":"1084","article-title":"Treatment of hypercholesterolemia with PCSK9 inhibitors in heart transplant recipients: first experience in Spain","volume":"72","author":"Groba-Marco","year":"2019","journal-title":"Rev\u00a0Esp\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210373","article-title":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation","volume":"14","author":"K\u00fchl","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2026.02.021_bib99","first-page":"S106","article-title":"Utilization of PCSK-9 inhibitors in statin intolerant cardiac transplant patients","volume":"26","author":"McCollum","year":"2020","journal-title":"J\u00a0Card\u00a0Fail"},{"key":"10.1016\/j.jacl.2026.02.021_bib100","first-page":"104.e1","article-title":"Safety and efficacy of PCSK9 inhibitors after heart transplantation","volume":"35","author":"Moayedi","year":"2019","journal-title":"Can\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib101","first-page":"812","article-title":"PCSK9 inhibitors in heart transplant patients: safety, efficacy, and angiographic correlates","volume":"27","author":"Sammour","year":"2021","journal-title":"J\u00a0Card\u00a0Fail"},{"key":"10.1016\/j.jacl.2026.02.021_bib102","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacl.2026.02.021_bib103","first-page":"4762","article-title":"PCSK9 and inflammatory biomarkers in the early post kidney transplantation period","volume":"25","author":"Melexopoulou","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jacl.2026.02.021_bib104","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jchf.2024.04.026","article-title":"Randomized trial of cholesterol lowering with evolocumab for cardiac allograft vasculopathy in heart transplant recipients","volume":"12","author":"Broch","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacl.2026.02.021_bib105","article-title":"Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: design of the randomized controlled EVOLVD trial","volume":"34","author":"Broch","year":"2020","journal-title":"Clin\u00a0Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib106","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib107","first-page":"321","article-title":"Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial","volume":"12","author":"Stroes","year":"2018","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"key":"10.1016\/j.jacl.2026.02.021_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib109","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib110","first-page":"111","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2026.02.021_bib111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2020.11.018","article-title":"EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study","volume":"316","author":"So","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.02.021_bib112","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jnutbio.2009.02.008","article-title":"Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages","volume":"21","author":"Mullen","year":"2010","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.jacl.2026.02.021_bib113","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/0002-9149(92)90463-9","article-title":"Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients","volume":"70","author":"Barbir","year":"1992","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib114","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/TP.0b013e318177281e","article-title":"Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients","volume":"86","author":"Celik","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jacl.2026.02.021_bib115","first-page":"1324","article-title":"Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients","volume":"29","author":"Andreassen","year":"1997","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib116","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.amjcard.2006.06.033","article-title":"Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients","volume":"98","author":"Harris","year":"2006","journal-title":"Amn J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib117","first-page":"428","article-title":"Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients","volume":"22","author":"Holm","year":"2001","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2026.02.021_bib118","first-page":"II281","article-title":"Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation","volume":"88","author":"Ventura","year":"1993","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.1016\/j.jacl.2026.02.021_bib119","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1017\/S0007114512001596","article-title":"Long chain omega-3 fatty acids and cardiovascular disease: a systematic review","volume":"107","author":"Delgado-Lista","year":"2012","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jacl.2026.02.021_bib120","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/0002-9149(93)90624-L","article-title":"Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil \u00b1 lovastatin","volume":"71","author":"Peters","year":"1993","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.021_bib121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-199702000-00006","article-title":"A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients","volume":"4","author":"Hanes","year":"1997","journal-title":"Am J Ther"},{"key":"10.1016\/j.jacl.2026.02.021_bib122","first-page":"613","article-title":"Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial","volume":"14","author":"Pflugfelder","year":"1995","journal-title":"J\u00a0Heart\u00a0Lung Transplant"},{"key":"10.1016\/j.jacl.2026.02.021_bib123","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","article-title":"Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association","volume":"131","author":"Kulik","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1524-6175.2005.05278.x","article-title":"Fibrates in combination with statins in the management of dyslipidemia","volume":"8","author":"Jacobson","year":"2006","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jacl.2026.02.021_bib125","first-page":"483","article-title":"Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation","volume":"72","author":"Fehrman-Ekholm","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.jacl.2026.02.021_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2026.02.021_bib127","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug-drug interactions","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.02.021_bib128","doi-asserted-by":"crossref","first-page":"M704","DOI":"10.1097\/00002480-199507000-00102","article-title":"Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients","volume":"41","author":"Jensen","year":"1995","journal-title":"ASAIO J"},{"key":"10.1016\/j.jacl.2026.02.021_bib129","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.02.021_bib130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.02.021_bib131","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/jcm11144080","article-title":"Dyslipidemia in transplant patients: which therapy?","volume":"11","author":"Iannuzzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib132","article-title":"Novel therapeutic strategies for dyslipidemia: first report of inclisiran therapy in a kidney transplanted patient","volume":"36","author":"Ueberdiek","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.jacl.2026.02.021_bib133","first-page":"1855","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib134","first-page":"e48","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler\u00a0Thromb\u00a0Vasc\u00a0Biol"},{"key":"10.1016\/j.jacl.2026.02.021_bib135","first-page":"2295","article-title":"Elevated lipoprotein A levels and development of moderate or severe cardiac allograft vasculopathy in patients with heart transplants","volume":"55","author":"Gonz\u00e1lez-Quijano","year":"2023","journal-title":"Transplant\u00a0Proc"},{"key":"10.1016\/j.jacl.2026.02.021_bib136","first-page":"711","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.jacl.2026.02.021_bib137","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1742-1241.2007.01488.x","article-title":"LDL-apheresis: indications and clinical experience in a tertiary cardiac centre","volume":"61","author":"Archontakis","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2026.02.021_bib138","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1567-5688(09)71803-3","article-title":"The Dresden Apheresis Center\u2014experience with LDL apheresis and immunoadsorption","volume":"10","author":"Julius","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2026.02.021_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(95)91034-O","article-title":"Regression of transplant coronary artery disease during chronic HELP therapy: a case study","volume":"115","author":"Park","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.02.021_bib140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1744-9987.2009.00749.x","article-title":"The first case report of the treatment of transplant coronary artery disease with dextran sulfate adsorption lipid apheresis","volume":"14","author":"Sosland","year":"2010","journal-title":"Ther Apher Dial"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:28:30Z","timestamp":1778761710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":140,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1933287426000541"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.021","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidemia and therapies after heart transplantation: Current\u00a0evidence and future directions","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}